Oral Salt and Water to Prevent Contrast Nephropathy

• Status: Withdrawn
• Trial end date: 2016-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this pilot trial is to determine the safety and feasibility of using oral salt and water loading compared to intravenous saline for the prevention of contrast-induced acute kidney injury in patients with chronic kidney disease receiving a contrast-enhanced CT scan.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ottawa Hospital Research Institute

Criteria

Inclusion Criteria:

• Chronic kidney disease (as defined by glomerular filtration rate (GFR) < 45 mL/min/1.73m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula calculated on the day of randomization);

• Undergoing an outpatient intravenous contrast-enhanced CT of the chest or abdomen;

• Age ≥ 18 years

Exclusion criteria:

• Inability to give informed consent;

• Previously enrolled in this study;

• Any contrast-enhanced test in previous 14 days (to exclude patients who might have ongoing AKI from previous contrast exposure) ;

• Congestive heart failure defined as New York Heart Association (NYHA) class III or worse 76;

• Uncontrolled hypertension defined as systolic blood pressure greater than 180 mm Hg or diastolic blood pressure greater than 110 mm Hg at screening;

• Receiving dialysis treatments.

• The Physician ordering the CT scan has also ordered IV Saline, sodium bicarbonate or n-acetyl cysteine.